Pac Cristina-Patricia, Sánchez-González José-María, Rocha-de-Lossada Carlos, Mercea Nadina, Ferrari Francis, Preda Maria Alexandra, Rosca Cosmin, Munteanu Mihnea
Department of Ophthalmology, University of Medicine and Pharmacy "Victor Babes", 300041 Timisoara, Romania.
Department of Physics of Condensed Matter, Optics Area, University of Seville, 41012 Seville, Spain.
Healthcare (Basel). 2024 May 30;12(11):1119. doi: 10.3390/healthcare12111119.
Dry eye disease (DED), a prevalent condition with a multifactorial etiology, significantly impacts global health by causing discomfort and visual disturbance. This historical cohort study evaluates the efficacy of Intense Pulsed Light (IPL) therapy on meibomian gland dysfunction (MGD)-related evaporative DED.
The study involved 110 patients (220 eyes) who underwent IPL therapy. Ethical approval was secured, and informed consent was obtained from all participants. A Tearcheck (ESWvision, Houdan, France) device was used for ocular surface evaluation, measuring tear film stability (NIFBUT, NIABUT), tear film quantity (CTMH, TTMH), and inflammation (OSIE). The study assessed tear film and ocular surface health across multiple IPL sessions.
Significant improvements were observed in subjective symptoms (EFT score increased from 29.10 ± 8.87 to 35.91 ± 7.03, < 0.01), tear film stability (NIFBUT increased from 9.37 ± 6.04 to 10.78 ± 5.83 s, < 0.01; NIABUT increased from 11.07 ± 4.98 to 12.34 ± 4.66 s, < 0.01), and tear film surface evaluation (TFSE score decreased from 337.78 ± 414.08 to 206.02 ± 240.44, < 0.01). Tear film quantity remained unchanged (CTMH and TTMH, > 0.05).
IPL therapy is a promising treatment for DED, improving symptoms and ocular surface health. Further research is warranted to explore long-term efficacy and optimization.
干眼疾病（DED）是一种病因多因素的常见病症，通过引起不适和视觉干扰对全球健康产生重大影响。这项历史性队列研究评估了强脉冲光（IPL）疗法对睑板腺功能障碍（MGD）相关蒸发型干眼的疗效。
该研究纳入了110例接受IPL治疗的患者（220只眼）。获得了伦理批准，并从所有参与者处获得了知情同意。使用泪液检查仪（法国胡丹ESWvision公司）进行眼表评估，测量泪膜稳定性（非侵入性泪膜破裂时间、侵入性泪膜破裂时间）、泪膜量（结膜囊泪液高度、泪湖泪液高度）和炎症（眼表炎症指数）。该研究评估了多个IPL疗程中的泪膜和眼表健康状况。
主观症状（眼表疾病指数量表评分从29.10±8.87提高到35.91±7.03，P<0.0）、泪膜稳定性（非侵入性泪膜破裂时间从9.37±6.04秒增加到10.78±5.83秒，P<0.01；侵入性泪膜破裂时间从11.07±4.98秒增加到12.34±4.66秒，P<0.01）和泪膜表面评估（泪膜表面评估评分从337.78±414.08降低到206.02±240.44，P<0.01）均有显著改善。泪膜量保持不变（结膜囊泪液高度和泪湖泪液高度，P>0.05）。
IPL疗法是一种有前景的干眼治疗方法，可改善症状和眼表健康。有必要进一步研究以探索其长期疗效和优化方案。
